CPIX Valuation

Cumberland Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

3.130

0(0.000%)1D

Overview
Forecast
Valuation
Earnings

CPIX Relative Valuation

CPIX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CPIX is overvalued; if below, it's undervalued.

Historical Valuation

Cumberland Pharmaceuticals Inc (CPIX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 7.32. The fair price of Cumberland Pharmaceuticals Inc (CPIX) is between NaN to NaN according to relative valuation methord.

Relative Value

Fair Zone

NaN-NaN

Current Price：3.13

Fair

0.00

Trailing

Forward

0.00

EV/EBITDA

Cumberland Pharmaceuticals Inc. (CPIX) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 5.04. The thresholds are as follows: Strongly Undervalued below -34.50, Undervalued between -34.50 and -14.73, Fairly Valued between 24.80 and -14.73, Overvalued between 24.80 and 44.57, and Strongly Overvalued above 44.57. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

1.32

EV/EBIT

Cumberland Pharmaceuticals Inc. (CPIX) has a current EV/EBIT of 1.32. The 5-year average EV/EBIT is -3.57. The thresholds are as follows: Strongly Undervalued below -14.03, Undervalued between -14.03 and -8.80, Fairly Valued between 1.65 and -8.80, Overvalued between 1.65 and 6.88, and Strongly Overvalued above 6.88. The current Forward EV/EBIT of 1.32 falls within the Historic Trend Line -Fairly Valued range.

0.00

Cumberland Pharmaceuticals Inc. (CPIX) has a current PS of 0.00. The 5-year average PS is 0.48. The thresholds are as follows: Strongly Undervalued below -0.57, Undervalued between -0.57 and -0.05, Fairly Valued between 1.01 and -0.05, Overvalued between 1.01 and 1.54, and Strongly Overvalued above 1.54. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

Cumberland Pharmaceuticals Inc. (CPIX) has a current P/OCF of 0.00. The 5-year average P/OCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/OCF of 0.00 falls within the Strongly Undervalued range.

34.41

P/FCF

Cumberland Pharmaceuticals Inc. (CPIX) has a current P/FCF of 34.41. The 5-year average P/FCF is 28.43. The thresholds are as follows: Strongly Undervalued below -86.78, Undervalued between -86.78 and -29.18, Fairly Valued between 86.04 and -29.18, Overvalued between 86.04 and 143.64, and Strongly Overvalued above 143.64. The current Forward P/FCF of 34.41 falls within the Historic Trend Line -Fairly Valued range.

Cumberland Pharmaceuticals Inc (CPIX) has a current Price-to-Book (P/B) ratio of 1.67. Compared to its 3-year average P/B ratio of 1.12 , the current P/B ratio is approximately 49.36% higher. Relative to its 5-year average P/B ratio of 1.06, the current P/B ratio is about 57.25% higher. Cumberland Pharmaceuticals Inc (CPIX) has a Forward Free Cash Flow (FCF) yield of approximately 15.72%. Compared to its 3-year average FCF yield of 16.10%, the current FCF yield is approximately -2.36% lower. Relative to its 5-year average FCF yield of 14.53% , the current FCF yield is about 8.20% lower.

1.67

P/B

Median3y

1.12

Median5y

1.06

15.72

FCF Yield

Median3y

16.10

Median5y

14.53

Competitors Valuation Multiple

The average P/S ratio for CPIX's competitors is 13.75, providing a benchmark for relative valuation. Cumberland Pharmaceuticals Inc Corp (CPIX) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of 10.04%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

CPIX.O

Cumberland Pharmaceuticals Inc

Tempest Therapeutics Inc

Loss

46.75M

ALGS.O

Aligos Therapeutics Inc

Telomir Pharmaceuticals Inc

Loss

48.10M

GRCE.O

Grace Therapeutics, Inc

Performance Decomposition

Market capitalization of CPIX increased by 131.85% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -5.69 to -14.88.

The secondary factor is the Revenue Growth, contributed 10.04%to the performance.

Overall, the performance of CPIX in the past 1 year is driven by P/E Change. Which is more unsustainable.

10.04%

9.85M → 10.84M

Revenue Growth

-39.46%

-11.20 → -6.78

Margin Expansion

161.27%

-5.69 → -14.88

P/E Change

131.85%